SCHEMBL3540905

SCHEMBL3540905

O=C(Cc1ccccc1)Nc1cccc(-c2nn3ccccc3c2-c2ccnc(Nc3ccccc3)n2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 4/20 0.65
MAPK8 P45983 5/20 0.58
MAPK9 P45984 5/20 0.58
MAPK10 P53779 1/20 0.58
KDR P35968 6/20 0.56
AURKA O14965 4/20 0.56
AURKB Q96GD4 4/20 0.56
CDK19 Q9BWU1 2/20 0.56
IGF1R P08069 10/20 0.54
RET P07949 4/20 0.54
STK3 Q13188 4/20 0.54
MAP4K5 Q9Y4K4 4/20 0.54
CSF1R P07333 3/20 0.54
PTK2 Q05397 3/20 0.54
MAP4K2 Q12851 3/20 0.54
FLT1 P17948 2/20 0.54
EGFR P00533 8/20 0.54
ERBB2 P04626 7/20 0.54
PRKD3 O94806 3/20 0.54
MAP4K4 O95819 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3548062 0.94 SLC2A1 (0.60) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL13118758 0.94 SLC2A1 (0.62) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL3545797 0.89 SLC2A1 (0.58) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL13118916 0.88 IGF1R (0.56) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL3542913 0.88 SLC2A1 (0.62) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL13105464 0.87 SLC2A1 (0.65) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL3539208 0.86 SLC2A1 (0.54) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL3545693 0.86 SLC2A1 (0.54) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL3536693 0.86 SLC2A1 (0.54) SLC2A1MAPK8MAPK9MAPK10KDR
SCHEMBL3543141 0.86 SLC2A1 (0.55) SLC2A1MAPK8MAPK9MAPK10KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971606-B1 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-04-24 EP disclosed
EP-1971606-B1 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-04-24 EP disclosed
US-7807673-B2 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-10-05 US disclosed
US-7807673-B2 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-10-05 US disclosed
US-7807673-B2 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-10-05 US disclosed
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors GLAXOSMITHKLINE LLC 2009-06-11 US disclosed
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors GLAXOSMITHKLINE LLC 2009-06-11 US disclosed
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors GLAXOSMITHKLINE LLC 2009-06-11 US disclosed
WO-2007067506-A2 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors ERBB2, ERBB3, ERBB4 SLC2A1 3810/4885MAPK8 263/4885MAPK9 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.